Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer

<p>Supplementary video 1</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Min Wei (16918572) (author)
Rannpháirtithe:	Xinping Huang (16918575) (author), Liming Liao (16918578) (author), Yonglu Tian (16918581) (author), Xiaofeng Zheng (16918584) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Cancer Biology Tumor Biology Molecular and Cellular Biology Cancer Detection and Diagnosis Therapeutic Research and Development Biochemistry Protein/protein interactions Biomarkers Protein biomarkers Carcinogenesis DNA damage and repair DNA Damage and Repair Drug Resistance Regulation of gene expression in drug resistance Gastrointestinal Cancers Colorectal cancer Oncogenes & Tumor Suppressors Oncogenes Progression, Invasion & Metastasis
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Supplementary Data from SENP1 Decreases RNF168 Phase Separation to Promote DNA Damage Repair and Drug Resistance in Colon Cancer
de réir: Min Wei (16918572)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer
de réir: Kavya Ramkumar (16474203)
Foilsithe / Cruthaithe: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
de réir: Craig M. Goodwin (14955973)
Foilsithe / Cruthaithe: (2025)

Figure 1 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
de réir: Marta J. Llorca-Cardenosa (14961612)
Foilsithe / Cruthaithe: (2025)

Figure 2 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
de réir: Marta J. Llorca-Cardenosa (14961612)
Foilsithe / Cruthaithe: (2025)

Figure 3 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
de réir: Marta J. Llorca-Cardenosa (14961612)
Foilsithe / Cruthaithe: (2025)

Figure 4 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
de réir: Marta J. Llorca-Cardenosa (14961612)
Foilsithe / Cruthaithe: (2025)

Figure 5 from SMG8/SMG9 Heterodimer Loss Modulates SMG1 Kinase to Drive ATR Inhibitor Resistance
de réir: Marta J. Llorca-Cardenosa (14961612)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes
de réir: Sanna Pikkusaari (15055802)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Supplementary Table from CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies
de réir: Long Jiang (14956159)
Foilsithe / Cruthaithe: (2025)

Figure 1 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 2 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 3 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Figure 4 from Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors
de réir: Katrina M. Lappin (9340394)
Foilsithe / Cruthaithe: (2025)

Supplementary Tables S1-S11 from <i>NBN</i> Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and <i>In Vitro</i> DNA Damage Response Defects
de réir: Sami Belhadj (15052341)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
de réir: Arun Kanakkanthara (14937731)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_lnmj3q6knuboipfr1n5h9k6ubd